Patents Issued in April 17, 2007
  • Patent number: 7204967
    Abstract: An apparatus and method for treating waste products produced by chemical processing plants. Steam stripping waste sour water results in a vapor including ammonia and hydrogen sulfide. A scrubber unit including a quenching column produces a concentrated ammonium sulfide solution. The concentrated ammonium sulfide allows for more efficient transfer from more than one refinery to a centralized purification facility for further processing.
    Type: Grant
    Filed: September 23, 2005
    Date of Patent: April 17, 2007
    Inventors: Scott A. Bierle, Richard Neylon, Allen D. Bierle
  • Patent number: 7204968
    Abstract: Energy in the form of heat is recoverable and controllable in a process that reacts an acid and a base in the presence of steam. The recovered heat energy can be used to vaporize water to form steam which when used in conjunction with a turbine will produce electricity.
    Type: Grant
    Filed: August 30, 2004
    Date of Patent: April 17, 2007
    Inventor: John V. Reints
  • Patent number: 7204969
    Abstract: A precipitated silica having the following physico-chemical characteristics: pH (5% in water) (ISO 787-9) 3–8 BET surface area (DIN 66131) (m2/g) 400–600 DBP absorption value (DIN 53601, (g/100 g) 380–420 in relation to dried substance) Tapped density (ISO 787-11) (g/l) 100–200 ALPINE sieve residue > 63? (ISO 8130-1) (%) 0.1–40.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: April 17, 2007
    Assignee: Degussa AG
    Inventors: Robert Kuhlmann, Karl Meier
  • Patent number: 7204970
    Abstract: The present invention discloses the process of supplying high pressure (e.g., 30 atmospheres) CO that has been preheated (e.g., to about 1000° C.) and a catalyst precursor gas (e.g., Fe(CO)5) in CO that is kept below the catalyst precursor decomposition temperature to a mixing zone. In this mixing zone, the catalyst precursor is rapidly heated to a temperature that results in (1) precursor decomposition, (2) formation of active catalyst metal atom clusters of the appropriate size, and (3) favorable growth of SWNTs on the catalyst clusters. Preferably a catalyst cluster nucleation agency is employed to enable rapid reaction of the catalyst precursor gas to form many small, active catalyst particles instead of a few large, inactive ones. Such nucleation agencies can include auxiliary metal precursors that cluster more rapidly than the primary catalyst, or through provision of additional energy inputs (e.g., from a pulsed or CW laser) directed precisely at the region where cluster formation is desired.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: April 17, 2007
    Assignee: William Marsh Rice University
    Inventors: Richard E. Smalley, Ken A. Smith, Daniel T. Colbert, Pavel Nikolaev, Michael J. Bronikowski, Robert K. Bradley, Frank Rohmund
  • Patent number: 7204971
    Abstract: The present invention is focused on a revolutionary, low-cost (highly-scaleable) approach for the mass production of three-dimensional microcomponents: the biological reproduction of naturally-derived, biocatalytically-derived, and/or genetically-tailored three-dimensional microtemplates (e.g., frustules of diatoms, microskeletons of radiolarians, shells of mollusks) with desired dimensional features, followed by reactive conversion of such microtemplates into microcomponents with desired compositions that differ from the starting microtemplate and with dimensional features that are similar to those of the starting microtemplate. Because the shapes of such microcomponents may be tailored through genetic engineering of the shapes of the microtemplates, such microcomposites are considered to be Genetically-Engineered Materials (GEMs).
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: April 17, 2007
    Assignee: The Ohio State University
    Inventor: Kenneth H. Sandhage
  • Patent number: 7204972
    Abstract: Modified annexins having an N-terminal chelation site comprising an amino acid extension are disclosed. The amino acid extension includes an amino acid sequence X1-Gly-X2, where X1 and X2 are selected from Gly and Cys, where at least one of X1 or X2 is Cys. Radionuclides are readily chelated by the modified annexins to provide radiolabeled annexins useful in imaging vascular thrombi and apoptosis in vivo.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: April 17, 2007
    Assignee: University of Washington
    Inventors: Jonathan F. Tait, David S. Brown
  • Patent number: 7204973
    Abstract: The invention relates to light-protective cosmetic or dermatological preparations that contain (a) at least one hydroxy-benzophenone, and (b) at last one dialkyl naphthalate of the structural formula (I), wherein R1 and R2 are independently selected form the group of the branched and unbranched alkyl groups that have 6 to 24 carbon atoms.
    Type: Grant
    Filed: November 2, 2002
    Date of Patent: April 17, 2007
    Assignee: Beiersdorf AG
    Inventors: Anja Göppel, Jens Schulz, Volker Wendel
  • Patent number: 7204974
    Abstract: The invention is a cosmetic or dermatological formulation, comprising: (a) at least one oxidation- and/or UV-sensitive active ingredient; (b) at least one dialkyl naphthalate which is characterized by the structural formula in which R1 and R2, independently of one another, are chosen from the group of branched and unbranched alkyl groups having 6 to 24 carbon atoms; and (c) at least one lipid with a polarity of at most 30 mN/m. The present invention also includes method of using the cosmetic or dermatological formulations.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: April 17, 2007
    Assignee: Beiersdorf AG
    Inventors: Guido Heinsohn, Anja Göppel, Volker Wendel
  • Patent number: 7204975
    Abstract: Cosmetic or dermatological formulations comprising at least one particulate UV filter substance and at least one dialkyl naphthalate having the structural formula wherein R1 and R2 are selected independently of one another from the group consisting of branched and unbranched alkyl groups having 6 to 24 carbon atoms, are useful for protecting skin from harmful effects of solar radiation, particularly from UV-A and UV-B radiation.
    Type: Grant
    Filed: February 27, 2004
    Date of Patent: April 17, 2007
    Assignee: Beiersdorf AG
    Inventors: Volker Wendel, Anja Göppel, Jens Schulz
  • Patent number: 7204976
    Abstract: The invention is a clear, elastomer-free, gel composition comprising: (a) 14–30 weight % of an antiperspirant active having a low metal to chloride ratio; (b) 7–23.3 weight % of one or more cyclomethicones having a flash point of 100 degrees C. or less; (c) 0.6–0.9 weight % of a silicone surfactant having an HLB value?8; (d) 30–70 weight % water; (e) 3.85–10 weight % of a water soluble glycol or polyglycol and (f) 0.1–3.0 weight % of a non-siliconized organic fragrance solubilizer; wherein the composition is a gel having a viscosity greater than 150,000 centipoise and a ratio of oil phase to water phase in the range of 10:90 to 24:76.
    Type: Grant
    Filed: May 30, 2003
    Date of Patent: April 17, 2007
    Assignee: Colgate-Palmolive Company
    Inventors: Christine Popoff, Suman Chopra, Mardoqueo Bustos, Xiaozhong Tang, Lin Fei
  • Patent number: 7204977
    Abstract: There is provided an oil-in-water emulsified composition comprising hydrophobic powder particles, a polyether-modified silicone represented by formula (1), and an ionic water-soluble polymer compound, whereby the succulent feel originating from thickening effect rendered by the ionic water-soluble polymer compound and the effects intrinsic to the hydrophobic powder particles can be demonstrated stably over time in an oil-in-water emulsified composition obtained using an ionic water-soluble polymer compound, to which composition the powder particles are added.
    Type: Grant
    Filed: July 15, 2003
    Date of Patent: April 17, 2007
    Assignee: Shiseido Co., Ltd.
    Inventors: Ayumi Asai, Yoshimasa Miura, Satoshi Tomomasa
  • Patent number: 7204978
    Abstract: A method of treating an infertility condition in humans or mammals, by exposure of a prospective mother to TGF beta or derivative or analog of TGF beta. The exposure is advantageously in conjunction with one more antigens of a prospective father so that a hyporesponsive immune reaction is mounted to the one or more antigens of the prospective father.
    Type: Grant
    Filed: March 6, 1998
    Date of Patent: April 17, 2007
    Assignee: The University of Adelaide
    Inventors: Sarah Anne Robertson, Kelton Paul Tremellen
  • Patent number: 7204979
    Abstract: Multipotent neural stem cell (MNSC) progeny are induced to generate cells of the hematopoietic system by placing the MNSC progeny in a hematopoietic-inducing environment. The hematopoietic-inducing environment can be either ex vivo or in vivo. A mammal's circulatory system provides an in vivo environment that can induce xenogeneic, allogeneic, or autologous MNSC progeny to generate a full complement of hematopoietic cells. Transplantation of MNSC progeny provides an alternative to bone marrow and hematopoietic stem cell transplantation to treat blood-related disorders.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: April 17, 2007
    Assignee: Neurospheres Holdings Ltd.
    Inventors: Christopher R. Bjornson, Rod L. Rietze, Brent A. Reynolds, Angelo L. Vescovi
  • Patent number: 7204980
    Abstract: The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric oxide levels in a patient, among others.
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: April 17, 2007
    Assignee: Phoenix Pharmacologics, Inc.
    Inventor: Mike Clark
  • Patent number: 7204981
    Abstract: Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition.
    Type: Grant
    Filed: March 21, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Angelina Vucic Ciaccia, Lawrence Mark Gelbert, Brian William Grinnell, Bryan Edward Jones, David Eugene Joyce
  • Patent number: 7204982
    Abstract: The invention provides a method for inhibiting proliferation of cancer cells, as well as methods for detecting and treating various cancers, including cancer of the brain, lung, breast, prostate and colon. The method comprises contacting a cancer cell with a molecule that disrupts the biological activity of a GDOX molecule. In one embodiment, the molecule is an antibody directed against a GDOX peptide. In other embodiments, the molecule is an antisense nucleotide directed against a GDOX nucleic acid molecule, or a vaccine comprising a GDOX peptide or a polynucleotide encoding a GDOX peptide. The invention additionally provides methods for detecting and treating cancer using GDOX-related molecules.
    Type: Grant
    Filed: July 2, 2002
    Date of Patent: April 17, 2007
    Assignee: The Regents of the University of California
    Inventor: Linda M. Liau
  • Patent number: 7204983
    Abstract: A composition for and a method of eliciting in a vertebrate a protective immune response against an eukaryotic parasite are disclosed. The method includes administering to the vertebrate a composition having a carrier group coupled to an oligosaccharide obtained from a lipoglycan found on the surface of an eukaryote. The composition is administered in an amount sufficient to elicit a protective immune response against the parasite.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: April 17, 2007
    Assignee: University of Massachusetts
    Inventor: Lloyd H. Semprevivo
  • Patent number: 7204984
    Abstract: Anti-acetyllysine monoclonal antibody capable of recognizing N?-acetyllysine regardless of the types of the adjacent amino acids. Namely, a monoclonal antibody having a light chain comprising a constant region having the amino acid sequence represented by SEQ ID NO:1 and a variable region having the amino acid sequence represented by SEQ ID NO:2 or an amino acid sequence derived from this amino acid sequence by deletion, substitution or addition of one to several amino acids, and a heavy chain comprising a constant region having the amino acid sequence represented by SEQ ID NO:3 and a variable region having the amino acid sequence represented by SEQ ID NO:4 or an amino acid sequence derived from this amino acid sequence by deletion, substitution or addition of one to several amino acids, and being capable of recognizing N?-acetyllysine in a protein regardless of the types of the adjacent amino acids, i.e.
    Type: Grant
    Filed: March 13, 2002
    Date of Patent: April 17, 2007
    Assignee: Japan Science and Technology Corporation
    Inventors: Yasuhiko Komatsu, Minoru Yoshida
  • Patent number: 7204985
    Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: April 17, 2007
    Assignees: Centocor, Inc., New York University
    Inventors: Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David Knight, Scott Siegel
  • Patent number: 7204986
    Abstract: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with ovarian cancer. The biological compositions can be used to retard the growth of ovarian cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: April 17, 2007
    Assignee: Ultra Biotech Limited
    Inventor: Ling Yuk Cheung
  • Patent number: 7204987
    Abstract: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with prostate cancer. The biological compositions can be used to retard the growth of prostate cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: April 17, 2007
    Assignee: Ultra Biotech Limited
    Inventor: Ling Yuk Cheung
  • Patent number: 7204988
    Abstract: The present invention relates to pharmaceutical compositions and dietary supplement comprising yeast cells that can produce a healthful benefit in a subject inflicted with breast cancer. The biological compositions can be used to retard the growth of breast cancer cells and/or prolonging the time of survival of the subject. The invention also relates to methods for manufacturing the biological compositions.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: April 17, 2007
    Assignee: Ultra Biotech Limited
    Inventor: Ling Yuk Cheung
  • Patent number: 7204989
    Abstract: A highly immunoreactive viral peptide, pE2, is disclosed which is derived from the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form. Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers.
    Type: Grant
    Filed: September 28, 2000
    Date of Patent: April 17, 2007
    Assignee: Yang Sheng Tang Company Limited
    Inventors: Hon Mun Ng, Stanley Im, Jizhong Zhang
  • Patent number: 7204990
    Abstract: A method is provided for attenuating a cytomegalovirus comprising functionally disrupting an open reading frame of a Toledo genome region or its homolog and making chimeric CMV virus genomes.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 17, 2007
    Assignee: MedImmune Vaccines, Inc.
    Inventors: George Kemble, Gregory M. Duke, Richard Spaete
  • Patent number: 7204991
    Abstract: The present invention relates to soluble P. gingivalis polypeptides derived from PG32 and PG33 and to polynucleotides encoding these polypeptides. The P. gingivalis polypeptides and nucleotides can be used in compositions for use in raising an immune response in a subject against P. gingivalis and treating or preventing or reducing the severity of the condition known as periodontitis or in other conditions related to infection with P. gingivalis.
    Type: Grant
    Filed: October 28, 2002
    Date of Patent: April 17, 2007
    Assignee: CSL Limited
    Inventors: Ian George Barr, Larissa Czajkowski, Bruce Carter Ross
  • Patent number: 7204992
    Abstract: Sequences encoding two immunoreactive glycoproteins were cloned from Ehrlichia canis (p153 gene) and Ehrlichia chaffeensis (p156 gene). These two glycoproteins are species-specific immunoreactive orthologs that are useful as subunit vaccines and for serologic and molecular diagnostics for E. canis and E. chaffeensis.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: April 17, 2007
    Assignee: Clayton Foundation for Research
    Inventors: Jere W. McBride, David H. Walker
  • Patent number: 7204993
    Abstract: A composition prepared from intact killed cells of isolated ?-hemolytic Streptococcus agalactiae and a concentrated extract of a culture of ?-hemolytic Streptococcus agalactiae, is effective for the protection of fish against infection by the same and other virulent strains Streptococcus agalactiae.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: April 17, 2007
    Assignee: The United States of America as represented by the Secretary of Agriculture
    Inventors: Joyce J. Evans, Phillip H. Klesius, Craig A. Shoemaker
  • Patent number: 7204994
    Abstract: The present invention relates to hormone coating layers having desirable hormone delivery characteristics and product lifetime. In one embodiment, the invention is a hormone composition including a substrate having an external surface, and a coating layer disposed on the external surface. The coating layer preferably includes a polymer web, a UV protectant material, and from about 1 wppm to about 100,000 wppm of a hormone dispersed throughout the polymer web. The invention also relates to methods for making hormone coating materials of the present invention. The coating compositions of the present invention preferably are implemented in human and animal food packaging materials in order to safely and efficiently protect the foodstuffs contained therein from insect infestation.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Ashland Licensing and Intellectual Property LLC
    Inventors: Timothy Jon Leeper, Joy Michelle Thomas, Amy Marie Nichols
  • Patent number: 7204995
    Abstract: A treatment for dry eye and other eye problems using a plug system or a delivery system. The plug system comprises solid, porous or hollow microcapsules composed of a biodegradable biocompatible polymer. The capsules are stored in the form of a powder that can be suspended in an aqueous carrier solution or dispersed in a gel or an ointment. Alternatively a biodegradable biocompatible capsule having a treating agent encapsulated within a polymer shell or a polymer sphere, again stored in the form of a powder that can be suspended in an aqueous carrier solution or dispersed in a gel or an ointment. The plug system prevents excretion of the capsules and their size is larger then the punctum and to prevent entrance to the lachrymal excretory system. The treatment is slowly released into the eye through the polymer shell or sphere and/or gets secreted as the polymer degrades.
    Type: Grant
    Filed: January 31, 2003
    Date of Patent: April 17, 2007
    Inventors: Dalia M. El-Sherif, Jeylan A. El-Mansoury
  • Patent number: 7204996
    Abstract: This invention comprises a method of treating a subject having relapsed or refractory cancer such as leukemia with liposomal annamycin including the steps of (a) evaluating the subject to determine if the subject has relapsed or refractory cancer; (b) administering a high-dose amount of liposomal-annamycin for at least 3 days in a 7 day period. First line cancer therapy with particular reference to leukemia is both contemplated and useful.
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: April 17, 2007
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael Andreeff, Elihu H Estey
  • Patent number: 7204997
    Abstract: A responsive microgel is provided which responds volumetrically and reversibly to a change in one or more aqueous conditions selected from the group consisting of (temperature, pH, and ionic conditions) comprised of an ionizable network of covalently cross-linked homopolymeric ionizable monomers wherein the ionizable network is covalently attached to an amphiphilic copolymer to form a plurality of ‘dangling chains’ and wherein the ‘dangling chains’ of amphiphilic copolymer form immobile micelle-like aggregates in aqueous solution. A responsive microgel is further provided that comprises at least one therapeutic entity and delivers a substantially linear and sustained release of the therapeutic entity under physiological conditions.
    Type: Grant
    Filed: November 18, 2002
    Date of Patent: April 17, 2007
    Assignee: Supratek Pharma Inc.
    Inventors: Lev E. Bromberg, Marina Temchenko
  • Patent number: 7204998
    Abstract: Perfuming or flavoring microcapsules that include a fireproofing agent in addition to a perfuming or flavoring ingredient and a carrier material, so that the microcapsules can reduce the occurrence or an explosion of reduced violence when suspended in hot air during their preparation. Also, methods of making these microcapsules and their use in perfumed, food, beverage or pharmaceutical products.
    Type: Grant
    Filed: July 2, 2003
    Date of Patent: April 17, 2007
    Assignee: Firmenich SA
    Inventors: Günter Holzner, André Moser
  • Patent number: 7204999
    Abstract: The method of the production of a nanoparticle of the present invention includes a step of forming a nanoparticle including a compound of ametal ion in a cavity part of aprotein, in a solution containing the protein having the cavity part therein, the metal ion, and a carbonate ion and/or a hydrogen carbonate ion. Examples of the aforementioned compound include e.g., a hydroxide. The aforementioned metal ion is preferably any one of a nickel ion (Ni2+), a chromium ion (Cr2+) or a copper ion (Cu2+). According to the aforementioned method, nanoparticles having a uniform particle diameter can be produced.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: April 17, 2007
    Assignee: Matsushita Electric Industrial Co., Ltd.
    Inventors: Mitsuhiro Okuda, Hideyuki Yoshimura, Ichiro Yamashita
  • Patent number: 7205000
    Abstract: A slurry comprising (a) sodium bicarbonate, (b) sodium chloride, and (c) water, in a weight ratio of (a)/(b) of about 2.5:1 to about 3.5:1, wherein upon further dilution of said slurry with additional water, the amount of sodium bicarbonate and sodium chloride which dissolves into said additional water is in the same ratio as said of (a)/(b) in said slurry before said additional dilution.
    Type: Grant
    Filed: April 4, 2002
    Date of Patent: April 17, 2007
    Assignee: Church & Dwight Co., Inc.
    Inventor: Mark D. Einziger
  • Patent number: 7205001
    Abstract: The invention relates to the use of arsenic compounds to treat a variety of neoplastic diseases. The present invention encompasses the administration to a mammal of arsenic in the form of a salt, complex, organic compound or ionic solution to treat tumors of epithelial tissue, connective tissue, central nervous system, lymphoid tissue, hematopoietic cells and tumors associated with oncogenic viruses. This invention also encompasses the treatment of hematopoietic disorders in mammals by the administration of one or more arsenic compounds to said mammal. Further, the arsenic compounds may be used to treat metastatic neoplastic diseases.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: April 17, 2007
    Assignee: Polarx Biopharmaceuticals, Inc.
    Inventors: Ralph M. Ellison, Fred H. Marmelstein
  • Patent number: 7205002
    Abstract: Pharmaceutical compositions containing elemental selenium (Se(0)), Se(0)-carrier conjugates, a chromophore photoproduct, fluorescent conjugates of the chromophore photoproduct and carrier molecules, or a mixture thereof are disclosed. Methods of using the pharmaceutical compositions such as inducing cell death are also disclosed. Further disclosed are methods of making the pharmaceutical compositions and components thereof.
    Type: Grant
    Filed: November 5, 2003
    Date of Patent: April 17, 2007
    Assignee: MCW Research Foundation, Inc.
    Inventors: Fritz Sieber, Wolfgang H. H. Günther, Jean-Pierre Daziano, Marianne Krieg-Kowald, Jamal Bousbaa, Raymond J. Bula
  • Patent number: 7205003
    Abstract: A composition and method are provided for alleviating the dermatological signs of intrinsic and extrinsic aging. A topical formulation containing a cosmeceutically active base, wherein the formulation provides a pH in the range of about 8.0 to 13.0 at the skin surface, is applied to the skin in order to prevent or treat aging-related skin conditions such as wrinkles, dry skin, age spots, sun damage (particularly UV radiation-induced oxidative stress), blemishes, hyperpigmented skin, age spots, increased skin thickness, loss of skin elasticity and collagen content, dry skin, lentigines and melasmas. The cosmeceutically active base is either an inorganic base, such as an inorganic hydroxide, an inorganic oxide, or a metal salt of a weak acid, or an organic base, particularly a nitrogenous base such as may be selected from primary amines, secondary amines, tertiary amines, amides, oximes, nitrites, aromatic and non-aromatic nitrogen-containing heterocycles, urea, and mixtures thereof.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: April 17, 2007
    Assignee: Dermatrends, Inc.
    Inventors: Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu
  • Patent number: 7205004
    Abstract: This invention provides a composition of herbs comprising Radix angelica sinensis (DangGui) 15–60%, Ligusticum chuanxiong (ChuanXiong) 5–20%, Hirudo (ShuiZhi) 3–7%, Polygonatum sibiricum (HuangJing) 4–15%. This invention further provides various uses of this composition.
    Type: Grant
    Filed: May 22, 2003
    Date of Patent: April 17, 2007
    Inventor: YongChao Xia
  • Patent number: 7205005
    Abstract: This present invention relates to a method for extracting Epimedium herb to prepare flavones and polysaccharides combinations in which their ratios vary from 2:8 to 8:2 by weight and applying these extracted compositions in treatment of prostatic hyperplasia. Total flavones of the extracts are in the range of 20–90% and the molecular weights of extracted polysaccharides vary from 1,000 to 700,000 Daltons. This invention also includes a method for preparing compounded formulations which contain extracts of Radix Ginseng, pollens, Radix Astragali, Cortex Phellodendri, Epimedium flavones and polysaccharides and administering these compositions directed at treatment of prostatic hyperplasia and prostatitis. Clinical study has showed that these extracts and formulations are effective in treatment of prostate illness with no adverse reactions.
    Type: Grant
    Filed: November 24, 2003
    Date of Patent: April 17, 2007
    Assignee: Bright Future Pharmaceutical Laboratories Limited
    Inventor: Hui Dong
  • Patent number: 7205006
    Abstract: A skin treatment composition comprising a Mahonia aquifolium extract in a liposome delivery system. The Mahonia aquifolium extract is present in the skin treatment composition in a range of from 5% to 20% by weight of the total composition. The skin treatment composition is particularly effective in the treatment of psoriasis, eczema and other dry skin conditions. The invention further provides a process for obtaining an extract of Mahonia aquifolium.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: April 17, 2007
    Assignee: Prime Pharmaceutical Corporation
    Inventors: Robert Mills, Rajiv Mathur, Nadya Lawrence
  • Patent number: 7205007
    Abstract: The invention provides a nutritional supplement system and program for patients undergoing or who have undergone a surgical or other invasive or stressful procedure, or who have suffered an injury. This nutritional supplement for the peri-operative period is designed to prevent deficiencies of nutrients needed for optimal health and healing during this period or for general application and to enable the person receiving the nutritional supplementation to achieve maximum healing and rapid recovery from a procedure or injury.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: April 17, 2007
    Assignee: Fairfield Clinical Trials, LLC
    Inventor: Edward M. Lane
  • Patent number: 7205008
    Abstract: A method for inhibiting the formation or persistence of brain amyloid deposits in a patient, including administering to the patient a therapeutically effective amount of plant matter from a plant of the genus Hypericum, species perforatum.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: April 17, 2007
    Assignee: ProteoTech, Inc.
    Inventors: Gerardo Castillo, Alan D. Snow
  • Patent number: 7205009
    Abstract: An herbal composition for the re-growth of human hair includes the combination of hypercium perforatum, veronica beccabunga, veronica officinalis, and equisetum arvense wherein the combination is infused in water and adapted to be applied to the scalp of a user.
    Type: Grant
    Filed: December 2, 2005
    Date of Patent: April 17, 2007
    Inventor: Dirk Stass
  • Patent number: 7205010
    Abstract: The invention provides a dietary supplement composition comprising ginger, Strobilanthes cusia, Panax pseudo-ginseng, Eucommia ulmoides, Momordicae grosvenori, Licorice root, and Allium fistulosum.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: April 17, 2007
    Inventor: Shinhan Sha
  • Patent number: 7205011
    Abstract: Disclosed herein are mixtures of turmeric extract oils. One mixture of turmeric oils is the hexane soluble fraction obtained by dissolving turmeric powder in hexane to form a hexane mixture, filtering the hexane mixture and evaporating the hexane from the turmeric oil mixture. A more refined turmeric oil combination is the oil left after the turmeric oil mixture is dissolved in hexane, placed on a silica gel/hexane chromatography column, and eluted with hexane into fractions that were then evaporated, thereby leaving the refined turmeric oil combination. Also disclosed are methods for treating inflammation, arthritis and rheumatoid arthritis and a pharmaceutical dosage form of the refined turmeric oil combination.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: April 17, 2007
    Assignee: Board of Regents, Acting for and on behalf of, University of Arizona
    Inventors: Guan Jie Chen, Robert Clark Lantz, Aniko M. Solyom, Barbara N. Timmermann, Shivanand D. Jolad
  • Patent number: 7205012
    Abstract: A scar reducing and massage emollient includes the mixing together of calendula flowers, chamomile flowers, comfrey leaf, rose petals, rosemary and rose geranium to form a herb mixture. Positioning the herb mixture in a cooking vessel and covering the herb mixture with almond oil and olive oil and heating the cooking vessel at a temperature below the boiling point of the olive and almond oils to define a heated mixture. Straining the heated mixture through cheesecloth to define a strained oil. Melting beeswax and mixing it with shea butter, lavender oil, Ylang Ylang oil, Aloe vera gel, jojoba oil, wheat germ oil, evening primrose oil and the strained oil to define an emollient. Positioning the emollient in at least one container.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: April 17, 2007
    Inventor: Wendy L. Hill
  • Patent number: 7205013
    Abstract: The present invention relates to genetically engineered recombinant respiratory syncytial viruses and viral vectors which contain deletions of various viral accessory gene(s) either singly or in combination. In accordance with the present invention, the recombinant respiratory syncytial viral vectors and viruses are engineered to contain complete deletions of the M2-2, NS1, NS2, or SH viral accessory genes or various combinations thereof. In addition, the present invention relates to the attenuation of respiratory syncytial virus by mutagenisis of the M2-1 gene.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: April 17, 2007
    Assignee: MedImmune Vaccines, Inc.
    Inventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
  • Patent number: 7205014
    Abstract: The present invention provides a method for producing a soymilk curd comprising steps of: adding a protein cross-linking enzyme into acid-treated soymilk adjusted at pH 5.4 to 6.4 by adding an acid to the soymilk; allowing proteins in the soymilk to form cross-links by maintaining the temperature at 20 to 60° C.; and allowing the cross-linked and acid-treated soymilk to coagulate by maintaining the temperature at 70 to 90° C. The present invention also provides a method for producing a soymilk curd comprising steps of: adding a protein cross-linking enzyme and sugars into acid-treated soymilk adjusted at pH 5.4 to 6.4 by adding an acid to the soymilk; allowing proteins in the soymilk to form cross-links by maintaining the temperature at 20 to 60° C.; and allowing the cross-linked and acid-treated soymilk to coagulate by maintaining the temperature at 70 to 90° C.
    Type: Grant
    Filed: March 11, 2004
    Date of Patent: April 17, 2007
    Assignee: Asahimatsu Foods Co., Ltd.
    Inventors: Takaaki Takebe, Nozomi Adachi, Masaki Tamura, Yoichi Katagiri
  • Patent number: 7205015
    Abstract: A method for producing a jerked meat rawhide chew toys has steps of forming rawhide chew toys, preparing neat, processing the meat, coating the rawhide chew toys with meat and drying the rawhide chew toys coated with meat. According to the method, the rawhide chew toys are coated with meat and jerked to improve dogs' desire to chew rawhide chew toys a long time to achieve the objective of cleaning dogs' teeth better.
    Type: Grant
    Filed: June 23, 2003
    Date of Patent: April 17, 2007
    Inventor: Chia-Lung Shu
  • Patent number: 7205016
    Abstract: A method of stacking packages, wherein an upper package has a configuration to avoid touching the contents of a lower package. The finished packages can be stacked within cartons for distribution and shipped long distances without causing damage to the contents of the trays in the lower position.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: April 17, 2007
    Assignee: SafeFresh Technologies, LLC
    Inventor: Anthony J. M. Garwood